Prostate Cancer

Volume 8 Number 9
September 2020

Home > Disciplines > Publications > Prostate Cancer Reviews > Volume 8, Year 2020 > Number 9, September


Case reports

Diagnosis, presentation

Epidemiology, risk factors, prevention

Etiology, pathogenesis, pathology

Follow-up, side effects, quality of life

Integrative medicine

Overall management

Prognosis, outcomes


Case reports

Purohit S, Bhaladhare S, Marathe N, Shah S, Raj A.
Small Cell Prostate Cancer with Atypical Presentation -A Case Report and Review of Literature.
J Orthop Case Rep. 2020;10(2):50-53. doi: 10.13107/jocr.2020.v10.i02.1692?. Case report & Review. _

Diagnosis, presentation

Bauman GS, Jani AB.
American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.
Pract Radiat Oncol. 2020 Sep 2. 2020:S1879-8500(20)30166-1. doi: 10.1016/j.prro.2020.06.009. Editorial; _

Becerra MF, Alameddine M, Zucker I, Tamariz L, Palacio A, Nemeth Z, Velasquez MC, Savio LF, Panizzutti M, Jue JS, Soodana-Prakash N, Ritch CR, Gonzalgo ML, Parekh DJ, Punnen S.
Performance of Multiparametric MRI of the Prostate in Biopsy Naïve Men: A Meta-analysis of Prospective Studies.
Urology. 2020 Sep 1. 2020;S0090-4295(20)31039-6. doi: 10.1016/j.urology.2020.06.102. Meta-analysis. _


Crocerossa F, Marchioni M, Novara G, Carbonara U, Ferro M, Russo GI, Porpiglia F, Di Nicola M, Damiano R, Autorino R, Cantiello F.
Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
J Urol. 2020 Sep 16. 2020;101097JU0000000000001369. doi: 10.1097/JU.0000000000001369. Review & Meta-analysis; _

Diao W, Cao Y, Su D, Jia Z.
Impact of 68Gallium prostate-specific membrane antigen tracers on the management of patients with prostate cancer who experience biochemical recurrence.
BJU Int. 2020 Sep 26. doi: 10.1111/bju.15257. Review & Meta-analysis. _

Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F, Zucchetta P.
PET/MRI in prostate cancer: a systematic review and meta-analysis.
Eur J Nucl Med Mol Imaging. 2020 Sep 8. doi: 10.1007/s00259-020-05025-0. Review & Meta-analysis. _

Frantzi M, Hupe MC, Merseburger AS, Schanstra JP, Mischak H, Latosinska A.
Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer.
Diagnostics (Basel). 2020 Aug 31. 2020;10(9):658. doi: 10.3390/diagnostics10090658. Review. _

French WW, Wallen EM.
Advances in the Diagnostic Options for Prostate Cancer.
Postgrad Med. 2020 Sep 8. doi: 10.1080/00325481.2020.1822067. Review. _

Gillies RJ, Schabath MB.
Radiomics Improves Cancer Screening and Early Detection.
Cancer Epidemiol Biomarkers Prev. 2020 Sep 11. 2020;cebp.0075.2020. doi: 10.1158/1055-9965.EPI-20-0075. Review. _

Hadaschik BA, Giesel FL, Chi K.
Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient Outcomes.
Eur Urol Focus. 2020 Sep 21. 2020;S2405-4569(20)30264-9. doi: 10.1016/j.euf.2020.09.005. Opinion. _

Hettiarachchi D, Geraghty R, Rice P, Sachdeva A, Nambiar A, Johnson M, Gujadhur R, Mcneill M, Haslam P, Soomro N, Zeeshan Hameed BM, Somani B, Veeratterapillay R, Rai BP.
Can the Use of Serial Multiparametric Magnetic Resonance Imaging During Active Surveillance of Prostate Cancer Avoid the Need for Prostate Biopsies?-A Systematic Diagnostic Test Accuracy Review.
Eur Urol Oncol. 2020 Sep 21. 2020:S2588-9311(20)30143-7. doi: 10.1016/j.euo.2020.09.002. Review. _

Piccardo A, Ugolini M, Righi S, Bottoni G, Cistaro A, Paparo F, Giovanella L, Evangelista L.
Copper, PET/CT and prostate cancer. A systematic review of the literature.
Q J Nucl Med Mol Imaging. 2020 Sep 9. doi: 10.23736/S1824-4785.20.03277-X. Review; _

Shaikh F, Dupont-Roettger D, Dehmeshki J, Kubassova O, Quraishi MI.
Advanced Imaging of Biochemical Recurrent Prostate Cancer With PET, MRI, and Radiomics.
Front Oncol. 2020 Aug 19. 2020;10:1359. doi: 10.3389/fonc.2020.01359. Opinion. _

Shaish H.
Structured prostate MRI reporting: how and why.
Abdom Radiol (NY). 2020 Sep 12. doi: 10.1007/s00261-020-02720-2. Review. _

Sharma U, Jagannathan NR.
Metabolism of prostate cancer by magnetic resonance spectroscopy (MRS).
Biophys Rev. 2020 Sep 12. 2020;12(5):1163-1173. doi: 10.1007/s12551-020-00758-6. Review. _

Sugano D, Sanford D, Abreu A, Duddalwar V, Gill I, Cacciamani GE.
Impact of radiomics on prostate cancer detection: a systematic review of clinical applications.
Curr Opin Urol. 2020 Nov;30(6):754-781. doi: 10.1097/MOU.0000000000000822. Review. _

Tucker D, Zheng W, Zhang DH, Dong X.
Circular RNA and its potential as prostate cancer biomarkers.
World J Clin Oncol. 2020 Aug 24. 2020;11(8):563-572. doi: 10.5306/wjco.v11.i8.563. Review. _

Uhr A, Glick L, Gomella LG.
An overview of biomarkers in the diagnosis and management of prostate cancer.
Can J Urol. 2020 Aug;27(S3):24-27. Review. _

Wang S, Frisbie J, Keepers Z, Bolten Z, Hevaganinge A, Boctor E, Leonard S, Tokuda J, Krieger A, Siddiqui MM.
The Use of Three-dimensional Visualization Techniques for Prostate Procedures: A Systematic Review.
Eur Urol Focus. 2020 Aug 29. 2020;S2405-4569(20)30215-7. doi: 10.1016/j.euf.2020.08.002. Review. _

Wang Z, Wang X, Wang WD, Zheng GY, Guo H, Zhang YS.
Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Predicting Prognosis of Surgically Resectable Urinary Cancers: Systematic Review and Meta-Analysis.
Chin Med Sci J. 2020 Jul 2. 2020;35(3):262-271. doi: 10.24920/003668?. Review & Meta-analysis. _

Yang L, Tan Y, Dan H, Hu L, Zhang J.
Diagnostic performance of diffusion-weighted imaging combined with dynamic contrast-enhanced magnetic resonance imaging for prostate cancer: a systematic review and meta-analysis.
Acta Radiol. 2020 Sep 9. 2020;284185120956269. doi: 10.1177/0284185120956269. Review & Meta-analysis. _

Epidemiology, risk factors, prevention

Takeshima Y, Suzuki M, Miyakawa J, Tsuru I, Yamada Y, Nakamura M, Sato Y, Kawai T, Yamada D, Morikawa T, Kume H.
Latent prostate cancer among Japanese males: a bibliometric study of autopsy reports from 1980-2016.
Jpn J Clin Oncol. 2020 Sep 2. 2020;hyaa161. doi: 10.1093/jjco/hyaa161. Bibliometric study. _

Etiology, pathogenesis, pathology

Carpenter VJ, Patel BB, Autorino R, Smith SC, Gewirtz DA, Saleh T.
Senescence and castration resistance in prostate cancer: A review of experimental evidence and clinical implications.
Biochim Biophys Acta Rev Cancer. 2020 Sep 18. 2020;1874(2):188424. doi: 10.1016/j.bbcan.2020.188424. Review. _

Cimadamore A, Cheng L, Lopez-Beltran A, Mazzucchelli R, Lucianò R, Scarpelli M, Montorsi F, Montironi R.
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review.
Eur Urol Oncol. 2020 Aug 31. 2020;S2588-9311(20)30127-9. doi: 10.1016/j.euo.2020.08.003. Review. _

Katongole P, Sande OJ, Joloba M, Reynolds SJ, Niyonzima N.
The human microbiome and its link in prostate cancer risk and pathogenesis.
Infect Agent Cancer. 2020 Aug 31. 2020;15:53. doi: 10.1186/s13027-020-00319-2. Review. _

Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E.
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications.
J Oncol. 2020 Sep 7. 2020;2020:4986365. doi: 10.1155/2020/4986365. Review. _

Powell IJ, Chinni SR, Reddy SS, Zaslavsky A, Gavande N.
Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the genetic/biologic mechanism of racial disparity: Update.
Urol Oncol. 2020 Sep 5. 2020:S1078-1439(20)30387-2. doi: 10.1016/j.urolonc.2020.08.019. Review. _

Saranyutanon S, Deshmukh SK, Dasgupta S, Pai S, Singh S, Singh AP.
Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research.
Cancers (Basel). 2020 Sep 17. 2020;12(9):2651. doi: 10.3390/cancers12092651. Review. _

Vellky JE, Ricke WA.
Development and prevalence of castration-resistant prostate cancer subtypes.
Neoplasia. 2020 Sep 25. 2020;22(11):566-575. doi: 10.1016/j.neo.2020.09.002. Review. _

Zhang E, Zhang M, Shi C, Sun L, Shan L, Zhang H, Song Y.
An overview of advances in multi-omics analysis in prostate cancer.
Life Sci. 2020 Sep 6. 2020;260:118376. doi: 10.1016/j.lfs.2020.118376. Review.. _ _

Follow-up, side effects, quality of life

Brunckhorst O, Hashemi S, Martin A, George G, Van Hemelrijck M, Dasgupta P, Stewart R, Ahmed K.
Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies.
Prostate Cancer Prostatic Dis. 2020 Sep 25. doi: 10.1038/s41391-020-00286-0. Review & Meta-analysis. _

Higano CS.
Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Urol Oncol. 2020 Sep 6. 2020:S1078-1439(20)30326-4. doi: 10.1016/j.urolonc.2020.07.004. Review. _

Odeo S, Degu A.
Factors affecting health-related quality of life among prostate cancer patients: A systematic review.
J Oncol Pharm Pract. 2020 Sep 25. 2020;1078155220959414. doi: 10.1177/1078155220959414. Review. _

Integrative medicine

Barbalata CI, Tefas LR, Achim M, Tomuta I, Porfire AS.
Statins in risk-reduction and treatment of cancer.
World J Clin Oncol. 2020 Aug 24. 2020;11(8):573-588. doi: 10.5306/wjco.v11.i8.573. Review. _

Crocetto F, Boccellino M, Barone B, Di Zazzo E, Sciarra A, Galasso G, Settembre G, Quagliuolo L, Imbimbo C, Boffo S, Angelillo IF, Di Domenico M.
The Crosstalk between Prostate Cancer and Microbiota Inflammation: Nutraceutical Products Are Useful to Balance This Interplay?
Nutrients. 2020 Aug 31. 2020;12(9):2648. doi: 10.3390/nu12092648. Review. _

Mehrzadi MH, Hosseinzadeh A, Juybari KB, Mehrzadi S.
Melatonin and urological cancers: a new therapeutic approach.
Cancer Cell Int. 2020 Sep 10. 2020;20:444. doi: 10.1186/s12935-020-01531-1. Review. _
Erratum in:
Cancer Cell Int. 2020 Sep 28. 2020;20:466. _ .

Santucci C, Gallus S, Martinetti M, La Vecchia C, Bosetti C.
Aspirin and the risk of nondigestive tract cancers: An updated meta-analysis to 2019.
Int J Cancer. 2020 Sep 27. doi: 10.1002/ijc.33311. Meta-analysis. _

Singh K, Jamshidi N, Zomer R, Piva TJ, Mantri N.
Cannabinoids and Prostate Cancer: A Systematic Review of Animal Studies.
Int J Mol Sci. 2020 Aug 29. 2020;21(17):6265. doi: 10.3390/ijms21176265. Review. _

Overall management

Gilligan T et al., PDQ Adult Treatment Editorial Board.
Prostate Cancer Treatment (PDQ®): Health Professional Version.
PDQ Cancer Inf Summ. 2020 Sep 23. NCBI Bookshelf: NBK66036. Review. _

Gutiontov SI, Pitroda SP, Weichselbaum RR.
Oligometastasis: Past, Present, Future.
Int J Radiat Oncol Biol Phys. 2020 Nov 1. 2020;108(3):530-538. doi: 10.1016/j.ijrobp.2020.02.019. Review. _

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
J Urol. 2020 Sep 22. 2020;101097JU0000000000001375. doi: 10.1097/JU.0000000000001375. Guidelines. _

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
J Urol. 2020 Sep 22. 2020;101097JU0000000000001376. doi: 10.1097/JU.0000000000001376. Guidelines. _

Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, Soule HR.
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
Prostate. 2020 Aug 31. doi: 10.1002/pros.24056. Meeting report. _

Shah A, Shah AA, K N, Lobo R.
Mechanistic targets for BPH and prostate cancer-a review.
Rev Environ Health. 2020 Sep 22. doi: 10.1515/reveh-2020-0051. Review. _

Schuettfort VM, Pradere B, Rink M, Comperat E, Shariat SF.
Pathomics in urology.
Curr Opin Urol. 2020 Nov;30(6):823-831. doi: 10.1097/MOU.0000000000000813. Review. _

Wake N, Nussbaum JE, Elias MI, Nikas CV, Bjurlin MA.
3D Printing, Augmented Reality, and Virtual Reality for the Assessment and Management of Kidney and Prostate Cancer: A Systematic Review.
Urology. 2020 Jun 11. 2020;143:20-32. doi: 10.1016/j.urology.2020.03.066. Review. _

Zaorsky NG, Spratt DE, Kishan AU, Culp SH, Showalter TN.
Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options.
Front Oncol. 2020 Aug 27;10:1616. doi: 10.3389/fonc.2020.01616. Editorial. _

Prognosis, outcomes

Saoud R, Heidar NA, Cimadamore A, Paner GP.
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer.
Cells. 2020 Sep 17. 2020;9(9):2116. doi: 10.3390/cells9092116. Review. _

Wright KM.
Two Retrospective Analyses Show No Associated Adverse Outcomes With Delayed RP.
Oncology (Williston Park). 2020 Sep 15. 2020;34(9):344-345. doi: 10.46883/ONC.2020.3409.0344. Perspective. _


Barani M, Sabir F, Rahdar A, Arshad R, Kyzas GZ.
Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates.
Nanomaterials (Basel). 2020 Aug 28. 2020;10(9):1696. doi: 10.3390/nano10091696. Review. _

Connor MJ, Smith A, Miah S, Shah TT, Winkler M, Khoo V, Ahmed HU.
Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
Eur Urol Oncol. 2020 Sep 3. 2020;3(5):582-593. doi: 10.1016/j.euo.2020.07.004. Review. _

Cuccia F, Mazzola R, Nicosia L, Giaj-Levra N, Figlia V, Ricchetti F, Rigo M, Vitale C, Corradini S, Alongi F.
Prostate re-irradiation: current concerns and future perspectives.
Expert Rev Anticancer Ther. 2020 Sep 10. 2020;1-10. doi: 10.1080/14737140.2020.1822742. Review. _


Dahm P, Brasure M, Ester E, Linskens EJ, MacDonald R, Nelson VA, Ryan C, Saha J, Sultan S, Ullman KE, Wilt TJ.
Therapies for Clinically Localized Prostate Cancer.
AHRQ Comp Eff Rev. 2020 Sep. Report No.: 20-EHC022. Review. _

Dror CM, Chi KN.
Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
Future Oncol. 2020 Sep 4. doi: 10.2217/fon-2020-0557. Review. _

Han HJ, Li YR, Roach M 3rd, Aggarwal R.
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.
Ther Adv Med Oncol. 2020 Aug 25. 2020;12:1758835920936084. doi: 10.1177/1758835920936084. Case report & Review. _

Handa S, Hans B, Goel S, Bashorun HO, Dovey Z, Tewari A.
Immunotherapy in prostate cancer: current state and future perspectives.
Ther Adv Urol. 2020 Sep 3. 2020;12:1756287220951404. doi: 10.1177/1756287220951404. Review. _

Hoy SM.
Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
Drugs. 2020 Sep 15. 2020;80(15):1579-1585. doi: 10.1007/s40265-020-01401-0. Review. _

Ihrig A, Maatouk I, Friederich HC, Baunacke M, Groeben C, Koch R, Thomas C, Huber J.
The Treatment Decision-making Preferences of Patients with Prostate Cancer Should Be Recorded in Research and Clinical Routine: a Pooled Analysis of Four Survey Studies with 7169 Patients.
J Cancer Educ. 2020 Sep 17. doi: 10.1007/s13187-020-01867-2. Pooled analysis. _

Khera M.
Controversies with testosterone therapy.
Can J Urol. 2020 Aug;27(S3):20-23. Review. _

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
Natl Inst Diabetes Dig Kidney Dis. 2020 Sep 7. NCBI bookshelf: NBK548533. Review. _

Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes RJ, Montorsi F, Gandaglia G; EAU-YAU Prostate Cancer Working Party.
Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
Eur Urol Oncol. 2020 Sep 12. 2020;3(5):565-581. doi: 10.1016/j.euo.2020.08.005. Review. _

Mayer C, Kumar A.
StatPearls Publ. 2020 Sep 15. NCBI Bookshelf: NBK562190. Review. _

Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O.
Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
Urol Oncol. 2020 Sep 18. 2020:S1078-1439(20)30370-7. doi: 10.1016/j.urolonc.2020.08.003. Review. _

Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Int J Clin Oncol. 2020 Sep 14. 2020;25(11):1892-1900. doi: 10.1007/s10147-020-01777-9. Review & Meta-analysis. _

Nizialek E, Antonarakis ES.
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Cancer Manag Res. 2020 Sep 7. 2020;12:8105-8114. doi: 10.2147/CMAR.S227033. Review. _

Okoye E, Saikali SW.
StatPearls Publ. 2020 Sep 3. NCBI Bookshelf: NBK562336. Review. _

Royce TJ, Mavroidis P, Wang K, Falchook AD, Sheets NC, Fuller DB, Collins SP, El Naqa I, Song DY, Ding GX, Nahum AE, Jackson A, Grimm J, Yorke E, Chen RC.
Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
Int J Radiat Oncol Biol Phys. 2020 Sep 5. 2020;S0360-3016(20)34102-X. doi: 10.1016/j.ijrobp.2020.08.014. Review. _

Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F.
Is There a Role for Immunotherapy in Prostate Cancer?
Cells. 2020 Sep 8. 2020;9(9):E2051. doi: 10.3390/cells9092051. Review. _

Satapathy S, Mittal BR, Sood A.
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Clin Nucl Med. 2020 Sep 15. doi: 10.1097/RLU.0000000000003307. Review & Meta-analysis; _

Southcott D, Awan A, Ghate K, Clemons M, Fernandes R.
Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer.
Curr Oncol. 2020 Aug 1. 2020;27(4):220-224. doi: 10.3747/co.27.6631. Review. _

Spratt DE, Tward JD.
Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy.
Int J Radiat Oncol Biol Phys. 2020 Sep 11. 2020;S0360-3016(20)31252-9. doi: 10.1016/j.ijrobp.2020.06.011. Editorial. _

Swerdloff R, Wang C.
Reflections on the T Trials.
Andrology. 2020 Sep 9. doi: 10.1111/andr.12901. Review. _

Tan G, Xuan Z, Li Z, Huang S, Chen G, Wu Y, Chen X, Liang Z, Wu A.
The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials.
Transl Androl Urol. 2020 Aug;9(4):1691-1699. doi: 10.21037/tau-20-1058. Meta-analysis. _